CCL4 (MIP-1β) in Long COVID

In Long COVID (PASC, Post-Acute Sequelae of COVID-19), published studies report higher levels of CCL4 (MIP-1β), also described as Chemokine, than in Non-COVID controls. Symptom domains tied to this marker in the source include elevated at 3 months post-infection. The evidence summarised here comes from Kallaste et al. 2025 and reflects averages across cohorts rather than any single patient's result.

↑ ElevatedInflammatory

Summary

Direction in Long COVID↑ Elevated — higher than in the comparison group
CategoryInflammatory
Also described asChemokine
Compared againstNon-COVID controls
Associated symptomsElevated at 3 months post-infection
Test typeBlood test (serum / plasma / whole blood)
SourceKallaste et al. 2025 — doi:10.3390/medicina61060996
Condition atlasLong COVID Biomarker Atlas

Trials, interventions and tests

In clinical-trial registrations this marker maps to the outcome term Assessment of Changes in Exosome/Cytokine/Chemokine Testing (4 registered trials use a matching outcome measure).

Clinical trials using CCL4 (MIP-1β) as an outcome

NCT05833217Recruiting
Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2
Outcome measure: Rate of Inflammatory Gene Expression in Adipose Tissue
NCT06535165Completed
Effect of Red Beetroot Juice Intake in Adults With Long COVID-19
Outcome measure: Changes in the concentration of circulating inflammatory mediators
Treatment of Long COVID Symptoms Utilizing Autologous Stem Cells Following COVID-19 Infection
Outcome measure: Assessment of Changes in Exosome/Cytokine/Chemokine Testing
VSL#3® vs Placebo in the Treatment of Fatigue and Other Symptoms in Long Covid (DELong#3)
Outcome measure: Analysis of PBMC and Serum Expression of inflammatory mediators at baseline (t0) and after 4 weeks of treatment (t4)

Related Inflammatory markers in Long COVID

Full list: Long COVID Biomarker Atlas.

Frequently asked questions

Is CCL4 (MIP-1β) high or low in Long COVID?

Elevated. Studies summarised in the OSMF atlas report higher CCL4 (MIP-1β) in Long COVID than in Non-COVID controls. Source: Kallaste et al. 2025.

What symptoms is CCL4 (MIP-1β) associated with in Long COVID?

The cited literature associates this marker with Elevated at 3 months post-infection. These are population-level associations and do not mean the marker causes the symptoms.

Which test measures CCL4 (MIP-1β)?

It is measured as a blood test (serum / plasma / whole blood). Many of the cited studies used research-grade assays, so clinical availability may vary.

Is one abnormal CCL4 (MIP-1β) result diagnostic of Long COVID?

No. No single biomarker is diagnostic of Long COVID. CCL4 (MIP-1β) findings come from group comparisons, overlap considerably between patients and controls, and vary with study design, timing and comparison group. A result should be interpreted by a clinician alongside symptoms, history and other tests.

Cite this page

Open Source Medicine Foundation. (2026). CCL4 (MIP-1β) in Long COVID: direction, evidence and what it means. OSMF Research Tracker. Retrieved November 21, 2026, from https://research.opensourcemed.info/biomarkers/long-covid/ccl4-mip-1beta.html

Last reviewed: 2026-06-29 · Page generated from long-covid.json · Browse: Long COVID atlas · Biomarker Index · All marker pages

Disclaimer: This page is an educational synthesis of published, peer-reviewed research and is not medical advice. Biomarker findings vary across studies with case definitions, comparison groups, timing and assay methods. Direction of change reflects the predominant finding in the cited source and does not establish a diagnostic threshold. Discuss any test result with a qualified clinician.